Sanofi To Present ALTUVIIIO's Long-Term Efficacy And Fitusiran's Prophylaxis Potential At ISTH
Portfolio Pulse from Benzinga Newsdesk
Sanofi is set to present new data on ALTUVIIIO and fitusiran at the ISTH conference, highlighting their potential in treating hemophilia. Interim results from the XTEND-ed phase 3 study show ALTUVIIIO's efficacy in bleed protection, while the ATLAS phase 3 study data support fitusiran's prophylactic potential. The FDA has accepted a New Drug Application for fitusiran, with a PDUFA date of March 28, 2025.
June 21, 2024 | 5:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi will present new data on ALTUVIIIO and fitusiran at the ISTH conference, showcasing their potential in hemophilia treatment. The FDA has accepted a New Drug Application for fitusiran, with a PDUFA date of March 28, 2025.
The presentation of new data at a major conference and the FDA's acceptance of a New Drug Application are positive developments for Sanofi. These events highlight the potential of their hemophilia treatments, which could lead to increased investor confidence and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100